Publication of prospectus in connection with SciBase’s preferential rights issue

The board of directors of SciBase Holding AB (publ) (”SciBase” or ”the Company”) has today published a prospectus in connection with the new share issue with preferential rights for the Company’s shareholders of approximately SEK 85 million, which was announced on 26 October 2017.

Prospectus approval and publication

The prospectus regarding the preferential rights issue has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the “SFSA”) and is now available on the Company’s website (www.scibase.com) and on Pareto Securities AB’s website (www.paretosec.com). The prospectus will also be available on the SFSA’s website (www.fi.se).

The preferential rights issue

On 26 October 2017, the board of directors in SciBase resolved to propose the general meeting to resolve on a preferential rights issue of up to SEK 85 million before deduction of transactions costs. On the extraordinary general meeting held 15 November 2017 it was resolved to approve the board’s proposal on a preferential rights issue.

Indicative timetable

22 November 2017                                  Record date. Shareholders who are registered in the Company’s share ledger kept by Euroclear Sweden AB on this day will be assigned subscription rights carrying the right to participate in the preferential rights issue

27 November – 7 December 2017       Trading in subscription rights

27 November – 11 December 2017     Subscription period

Around the 14 December 2017             The outcome of the rights issue is announced

Around the 27 December 2017             The rights issue is completed and registered

Financial and legal advisers

Pareto Securities AB is financial adviser to SciBase and Setterwalls Advokatbyrå AB is legal adviser to SciBase and Pareto Securities AB in the preferential rights issue. Avanza Bank is the Company’s certified adviser.

For further information, please contact:

Simon Grant, CEO
Phone: +46 72 887 43 99, e-mail:
simon.grant@scibase.se 

Michael Colérus, CFO

Phone: +46 70 341 34 72, e-mail: michael.colerus@scibase.se  

The information was submitted for publication, through the agency of the contact persons set out above, at 16:30 CET on 20 November, 2017.

About SciBase

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies.

SciBase is listed on Nasdaq First North (“SCIB”). Further information about the Company is available at www.scibase.com

IMPORTANT INFORMATION

This press release is not an offer or solicitation to acquire shares in SciBase. A prospectus relating to the preferential rights issue referred to in this press release have been drawn up and filed with the Swedish Financial Supervisory Authority.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. SciBase does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Canada, Australia, New Zealand, Singapore, South Africa, Japan or Hong Kong or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

About Us

SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of research at Karolinska Institute in Stockholm and at SciBase. The device is designed to be provide additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result. A video describing the Nevisense method is available on: www.scibase.se/en/the-nevisenseproduct and further information is also available on www.scibase.com.

Subscribe

Documents & Links